Want to see GTBP full AI Analyst Report?
GTBP Stock Chart & Stats
$0.29
-$0.01(-3.25%)
At close: 4:00 PM EDT
$0.29
-$0.01(-3.25%)
Day’s Range― - ―
52-Week Range$4.91 - $28.77
Previous CloseN/A
Volume415.79K
Average Volume (3M)97.00K
Market Cap
$14.49M
Enterprise Value$13.96M
Total Cash (Recent Filing)$4.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Nov 11, 2026EPS Estimate
-2.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-104.00
Shares Outstanding2,061,052
10 Day Avg. Volume38,319
30 Day Avg. Volume96,999
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$3.00Price Target Upside934.48% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-8.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Immuno-oncology PipelineThe company is focused on a specialized immuno-oncology platform using TriKE and related multispecific biologics. If clinical development succeeds, these approaches could support differentiated treatments across hematologic malignancies and potentially solid tumors.
No DebtA debt-free balance sheet avoids interest and refinancing pressure, preserving more flexibility for research spending and capital allocation. This is a meaningful structural advantage for a clinical-stage company whose future funding needs depend on development progress.
Nasdaq Compliance RestoredRegaining Nasdaq minimum bid compliance secures continued listing on the Nasdaq Capital Market through the reported period. Maintaining that access supports market visibility, shareholder liquidity, and the company’s ability to use public capital markets.
Bears Say
Pre-revenue And Loss-makingGT Biopharma remains pre-commercial, so its operating model has not yet demonstrated recurring revenue or profitability. Continued sizable losses leave earnings dependent on successful clinical advancement and eventual commercialization rather than established business operations.
Persistent Cash BurnSustained negative operating and free cash flow indicates that the company cannot currently fund operations internally. The re-accelerated burn increases dependence on external financing and can constrain the pace and durability of clinical development.
Thin, Shrinking Balance SheetAlthough debt is absent, the shrinking asset base and volatile equity cushion reduce financial resilience. A limited balance sheet provides less capacity to absorb development setbacks or sustain operations, making future capital raising more important.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $4.91 and its highest was $28.77 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $14.49M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Nov 11, 2026 which is in 23 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on Aug 14, 2026. The company reported -$3 earnings per share for the quarter, missing the consensus estimate of -$2 by -$1.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Undervalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -2.5.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 2,061,052 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$3 in its last earnings report, missing expectations of -$2. Following the earnings report the stock price went down -0.471%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
GTBP Stock 12 Month Forecast
Average Price Target
$3.00
▲(934.48% Upside)
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
―
Insiders
23.26% Mutual Funds
<0.01% Other Institutional Investors
76.00% Public Companies and
Individual Investors